MN Wealth Advisors LLC Has $296,000 Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

MN Wealth Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 35.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 594 shares of the medical research company’s stock after acquiring an additional 154 shares during the quarter. MN Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $296,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company’s stock valued at $17,297,426,000 after buying an additional 196,864 shares during the last quarter. Capital World Investors lifted its holdings in Thermo Fisher Scientific by 1.1% in the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company’s stock worth $4,905,812,000 after purchasing an additional 104,343 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Thermo Fisher Scientific by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company’s stock worth $4,075,540,000 after purchasing an additional 197,442 shares during the last quarter. Norges Bank acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $3,149,754,000. Finally, Northern Trust Corp lifted its holdings in Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company’s stock worth $2,034,107,000 after purchasing an additional 455,004 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

TMO opened at $390.17 on Wednesday. The stock has a market cap of $147.29 billion, a PE ratio of 22.88, a P/E/G ratio of 2.14 and a beta of 0.78. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 1 year low of $389.86 and a 1 year high of $627.88. The stock’s 50 day simple moving average is $415.31 and its 200-day simple moving average is $490.41.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the business posted $5.11 earnings per share. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is 10.09%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Barclays reduced their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Scotiabank reduced their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a report on Friday, April 25th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 23rd. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Finally, Argus dropped their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $605.30.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.